A Phase 1, Single-Dose, Randomized, Open-Label, Parallel Group Study to Assess the Relative Bioavailability and Tolerability of Two Formulations of Crenezumab in Healthy Subjects Following Subcutaneous Administration
Phase of Trial: Phase I
Latest Information Update: 14 Mar 2016
At a glance
- Drugs Crenezumab (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Genentech
- 09 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 May 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Apr 2015 New trial record